Department of Neurology, Qilu Hospital, Shandong University, Jinan 250012, China Great Wall Hospital of Jinan, Jinan 250100, China Jinnan 4th People Hospital, Jinan 250014, China Taishan Medical College, Jinan 271000, China General Hospital of Shangdong Garrison Command, Jinan 250002, China
刊名
Chinese Pharmaceutical Journal
年份
2005
卷号
Vol.40 No.8
页码
634-636
ISSN
1001-2494
摘要
OBJECTIVE: To study the efficacy and safety of low-molecular-weight heparin calcium and aspirin on treating acute cerebral infarction. METHODS: 240 cases with acute cerebral infarction were divided into four groups: the group treated with low-molecular-weight heparin calcium, the group treated with aspirin, the group treated with combined low-molecular-weight heparin calcium and aspirin and control group. The score of neurological defect scores, clinical effect and brain CT changes were observed...更多
OBJECTIVE: To study the efficacy and safety of low-molecular-weight heparin calcium and aspirin on treating acute cerebral infarction. METHODS: 240 cases with acute cerebral infarction were divided into four groups: the group treated with low-molecular-weight heparin calcium, the group treated with aspirin, the group treated with combined low-molecular-weight heparin calcium and aspirin and control group. The score of neurological defect scores, clinical effect and brain CT changes were observed before and after treatment. RESULTS: The neurological defect scores and clinical effect of cases in three treatment groups were apparently better than those in control group. The neurological defect scores and clinical effects in the group treated with combined low-molecular-weight heparin calcium and aspirin were apparently better than those in the group treated with low-molecular-weight heparin calcium or aspirin. CONCLUSION: The earlier treatment of acute cerebral infarction with low-molecular-weight heparin calcium and aspirin is safe and effective.收起
